# Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)

> **NCT01432535** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 25 (actual)

## Conditions studied

- Renal Insufficiency

## Interventions

- **DRUG:** PegIFN-2b (Sylatron®)

## Key facts

- **NCT ID:** NCT01432535
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01432535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01432535, "Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01432535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*